Pyxis Oncology prices Nasdaq IPO (1239334)
October 08 2021 - 2:00AM
UK Regulatory
Arix Bioscience PLC (ARIX) Pyxis Oncology prices Nasdaq IPO
08-Oct-2021 / 07:00 GMT/BST Dissemination of a Regulatory
Announcement, transmitted by EQS Group. The issuer is solely
responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Pyxis Oncology prices Nasdaq IPO
LONDON, 8 October 2021: Arix Bioscience plc (LSE: ARIX, "Arix"),
a global venture capital company focused on investing in and
building breakthrough biotech companies, today notes that its
portfolio company, Pyxis Oncology, Inc., ("Pyxis"), has announced
the pricing of its initial public offering of 10,500,000 shares of
common stock at a public offering price of USD16.00 per share for
aggregate gross proceeds of USD167.2m million. In addition, Pyxis
has granted the underwriters an option for a period of 30 days to
purchase up to 1,575,000 additional shares of common stock. All of
the shares are being offered by Pyxis. Pyxis' common stock is
expected to begin trading on the Nasdaq Global Market on 8 October
2021 under the ticker symbol "PYXS".
The IPO resulted in an GBP7.9million[1] (553p per share)
increase in the value of Arix's existing holding in Pyxis, which
was valued at GBP10.8 million at 30 June 2021. Mark Chin, Arix
Managing Director, will continue to serve on Pyxis' board.
A registration statement relating to these securities has been
filed with and declared effective by the U.S. Securities and
Exchange Commission. This announcement does not constitute an offer
to sell or the solicitation of an offer to buy securities, and
shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities Act
of 1933, as amended.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Manel Mateus
+44 (0)20 8078 4357
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences. We collaborate with
exceptional entrepreneurs and provide the capital, expertise and
global networks to help accelerate their ideas into important new
treatments for patients. As a listed company, we are able to bring
this exciting growth phase of our industry to a broader range of
investors.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a preclinical oncology company focused
on developing an arsenal of next-generation therapeutics to target
difficult-to-treat cancers and improve quality of life for
patients. Pyxis develops its product candidates with the objective
to directly kill tumor cells, and to address the underlying
pathologies created by cancer that enable its uncontrollable
proliferation and immune evasion. Since its launch in 2019, Pyxis
has developed a broad portfolio of novel antibody drug conjugate,
or ADC, product candidates, and monoclonal antibody, or mAb,
preclinical discovery programs that it is developing as
monotherapies and in combination with other therapies.
[] At exchange rate on 7 October 2021
[2] Cash cost of Arix at prevailing exchange rate at time of
investment
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 123861
EQS News ID: 1239334
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1239334&application_name=news
(END) Dow Jones Newswires
October 08, 2021 02:00 ET (06:00 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024